The FDA has approved a supplemental new drug application for Valtrex (valacyclovir HCI) manufactured by GlaxoSmithKline.
Study Compares Dose Escalation with Biologics in Psoriasis
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Publishing Excellence Runs More Than Skin Deep
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Oral Zasocitinib Demonstrates Safety and Efficacy in Moderate to Severe Plaque Psoriasis
Derm In The News: September 1-7